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INTRODUCTION
Ventilator-associated pneumonia (VAP) is a 
pulmonary infection that occurs after 48-72 hours 
after endotracheal intubation and/or mechan-
ical ventilator.1 Conceptually, it is defined as an 
inflammation of the lung parenchyma caused by 
an infectious agent that incubates as the mechan-
ical ventilation begins. According to the CDC 
(The Center of Disease Control and Prevention) 
National Healthcare Safety Network (NHSN) 
data, Ventilator-associated pneumonia is the 
most healthcare-associated infection occurred 
in the intensive care unit, and nearly 90% of the 
episodes occur when using mechanical ventila-
tion for up to 5.8 per 1,000 ventilators per day.2 
The incidence rate is varied in different studies 
depending on definition, type of hospital or ICU, 
population of the study and level of exposure 
to antibiotics.3 It varies between 9% - 27% in 
Europe and America with mortality about 20% 
-50% and may reach 70% in MDRO (Multi-drug 
resistant organisms) infection. The VAP accounts 
for almost 80% of hospital-acquired pneumonia 
and occurs in 8% to 28% of intubated patients.4 
A Systematic Review shows that VAP occurs in 
10% -20% of patients with mechanical ventilation 
for more than 48 hours and it has been estimated 
to increase mortality by 30% and even double in 
critical patients. 
The initial assessment of the disease severity is 
important for managing patients with VAP and 
those who are associated with disease prognosis. To 
improve the outcomes in the management of VAP, 
there has recently been a significant attention paid 
to focus on the use and implication of a simple, vali-
dated, evidence-based scoring systems and biolog-
ical markers to justify hospital admission in either 
acute medical settings or ICU, and to classify the 
disease severity which will help in predicting the 
life expectancy, mortality rate, and prognosis.5 The 
scoring systems for the critical patient in ICU have 
been introduced and developed since 30 years ago, 
but currently, no such similar disease-based scoring 
system is in use for VAP. Therefore, in clinical trials 
of VAP, the enrolled patient cohort is very hetero-
geneous with varied mortality risks, thus incorpo-
ration of severity scoring, risk adjustment, clinical 
scores or biomarkers in clinical trials of VAP may 
be a significant advancement.1,5 
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ABSTRACT
Ventilator-associated pneumonia (VAP) is a pulmonary infection that 
occurs as a mechanical ventilator-related disease which accounts for 
almost 80% of hospital-acquired pneumonia with of high mortality rate, 
lengthens the hospital-stay rate and increases health costs. To provide a 
description of the likelihood of the patient’s life expectancy, mortality, 
and prognosis of patients in ICU, a scoring system should be utilized in 
order to assess the severity of the disease and estimate mortality during 
hospital treatment. The PIRO scoring system is a comprehensive concept 
that provides good validity and derivation in predicting mortality risk 
in a wide range severity of the disease so that it is very useful in the 
selection or categorization of patients, especially those admitted to the 
ICU with VAP. A conjunction or integration with a simple biomarker such 
as Neutrophil-to-lymphocyte ratio (NLR) provides a better performance 
of the tool in regards to the predictive value in VAP mortality risk 
estimation. Since the NLR has a strong predictive value, is simple, low-
cost, and easily available compared to other biomarkers, therefore it is 
practical and useful for prognostic indications for VAP with conjunction 
with the PIRO score where medical facilities are lacking.
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CLINICAL SCORES IN PREDICTING  
MORTALITY FOR PATIENT WITH  
VENTILATOR ACQUIRED PNEUMONIA  
IN INTENSIVE CARE UNIT
There are a few numbers of surrogate measure-
ments for severity of disease and assessment 
scores frequently used to predict mortality in VAP 
clinical trials, such as the Predisposition, Insult, 
Response, and Organ dysfunction (PIRO), the 
Acute Physiology and Chronic Health Evaluation 
score (APACHE II, APACHE III, and APACHE 
IV) as measurements for overall severity of illness, 
and Sequential Organ Failure Assessment (SOFA) 
score as a measurement for organ dysfunction and 
failure.1,5 We have conducted a comprehensive 
search regarding identification of disease severity, 
short and long-term mortality among VAP patients 
cohort in MEDLINE, PubMed, and Google Scholar. 
The scoring system that commonly used 
at hospital admission is APACHE (Acute 
Physiological and Chronic Health Evaluation). 
This score was divided into a physiology score to 
assess the degree of the acute illness and pread-
mission condition to assess the chronic health 
status of the patient.6 The original model was then 
revised and simplified into APACHE II, III and 
IV. The standard scoring system commonly used 
for patients with pneumonia in ICUs is APACHE 
II.7,8,9 APACHE II is a computer-based ICU scor-
ing system with maximum points of 71 based on 
12 physiological variables i.e. patient’s age, oxygen 
partial pressure (PaO2), body temperature, mean 
arterial pressure, arterial pH, heart rate, respira-
tory rate, serum sodium, serum potassium, creat-
inine, hematocrit, white blood cell count (WCC), 
and Glasgow Coma Scale (GCS).9 It is applied 
within 24–hours of ICU admission to describe 
patient’s morbidity, assess the disease severity 
and mortality risk. Despite the common use, the 
APACHE II is recognized as having a number of 
important drawbacks, some of which relate to 
the simplicity and performance of the scale. The 
APACHE II is a complex and well-calibrated scor-
ing system; however, it requires data that are not 
available in the ED for all health facilities and does 
not include all patient risk factors or predisposi-
tion and is applied only for critical patients with 
limited varying severity.6,10 
The SOFA score was based on 4 laboratory 
parameters and 2 clinical parameters for their 
assessment, including PaO2/FiO2, mean arterial 
pressure, bilirubin, platelets, creatinine, and GCS. 
It is used to determine the extent of a person’s 
organ function and rate of failure11,12 during ICU 
stay. It has been shown that the SOFA scores help in 
predicting survival in patients with VAP-associated 
sepsis. A data from multicenter prospective trials 
on VAP (PNEUMA Trial) was confirmed that organ 
dysfunction measured by SOFA was an indepen-
dent predictor of VAP recurrence and mortality.1 In 
addition, acute refractory multiple organ dysfunc-
tion syndromes were the most frequent cause of 
death in the ICU (47%) in a study involving 3700 
patients admitted to an adult ICU.1
However, the SOFA score uses only physiologic 
and laboratory variables but does not consider host 
factors such as age, ethnicity, and comorbid disease 
burden, which are important drivers of mortality 
in VAP with sepsis. It is also considered to be less 
practical and some assessment parameters are still 
not available at some health facilities i.e. PaO2/
FiO2 and bilirubin level, so the modified Modified 
Sequential Organ Failure Assessment (MSOFA) is 
developed.13,14 The MSOFA developed was initially 
applied to critical care triage in the United States. 
Currently, SOFA scoring is widely used due to its 
simplicity and good validity, but it still does not 
include the patient risk factors or predisposition, 
and can not stratify the severity of the critical 
patients.
In recognition of host and virulence of patho-
gen factors, the Predisposition Insult Response and 
Organ failure (PIRO) model has been proposed to 
reflect each of those domains. The PIRO model is 
a system that first proposed by the International 
Sepsis Definitions Conference in 2001 which 
quantitatively categorizes the relationship between 
the patient’s premorbid state, type of infection, the 
degree of patient response and organ dysfunction. 
This single scoring system combines both severity 
and/or acuity of illness and organ dysfunction and 
provides disease stratification by both baseline risk 
of unfavorable outcome and response to therapy. 
This model is more useful in VAP clinical trials 
to predict 28-day mortality rate in VAP patients 
in ICU and associated with increased healthcare 
resource utilization in these patients.15 PIRO has 
been validated not only for critical patients but also 
for patients with varying severity, thus provides 
good validity and derivation in predicting mortal-
ity risk in a wide range of patients so that it is very 
useful in the selection or categorization of patients, 
especially those admitted to the ICU. 
This concept is based on predisposition (P) 
parameters, insult/infection (I), host response 
(R) and dysfunction organ (O). This idea was 
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designed to discriminate morbidity from infection 
and morbidity of the host response to infection. 
PIRO concept can serve as an accurate predictor 
of mortality in internal and external validation 
cohorts. 
Recently, an early version of the PIRO staging 
model for risk stratification in severe sepsis devel-
oped with classification was used to obtain a scoring 
system and was validated by using 2 (two) global 
databases of patients with severe sepsis (840 and 
10,610 patients).16 The PIRO VAP score was then 
developed as a concept for stratifying the risk of 
death of patients with VAP in the ICU. A prospec-
tive observational cohort study was conducted by 
Lisboa T. et al (2008) which included 441 patients 
with VAP in 3 multidisciplinary ICUs.17 The inde-
pendent variables associated with ICU mortality 
were analyzed by multivariate logistic regression. 
The results revealed the presence of a significant 
4-variable score for ICU mortality risk stratifica-
tion in patients with VAP (p <0.001), including 
(1) comorbidity (chronic obstructive pulmonary 
disease, immunocompromised state, cardiac fail-
ure, cirrhosis, or chronic renal failure, (2) bacte-
remia , (3) 90 mmHg systolic blood pressure, and 
(4) acute respiratory distress syndrome.3,17 On the 
basis of the observed ICU mortality according to 
VAP PIRO score, the patients were stratified into 
three levels of risk: (1) mild, 0 to 1 point; (2) high, 
2 points; and (3) very high, 3 to 4 points. In Cox 
regression analysis among the group at high risk 
and very high risk, the VAP PIRO score was related 
with higher risk of death with hazard ratio 2.14 (95% 
CI, 1.19–3.86) and 4.63 (95% CI, 2.68–7.99) respec-
tively. When compared with the APACHE II score, 
the VAP PIRO score performed better and was 
well-discriminated for ICU mortality (ROC AUC, 
0.81 [95% CI, 0.77–0.85] vs ROC AUC, 0.53 [95% 
CI, 0.47–0.58]; p<0.001). The authors concluded 
that the VAP PIRO score is the first approach to 
stratify patients corresponding to the severity of the 
VAP episode. It would be useful either to measure 
or to balance severity in randomized clinical trials 
since it is a simple and practical clinical tool for 
predicting ICU mortality.3,17
Another study by Howell et  al.18 proved that 
the PIRO classification approach provides better 
phenotypic characterization of patients with several 
dimensions of severity, therefore this approach can 
stratify patients better, predict mortality accurately 
in both its derivation and internal and external 
validation cohorts, and also determine the prog-
nostic of critical patients in the ICU. The study was 
conducted at two large US tertiary care centers with 
three independent, observational, and prospective 
cohorts. A derivation cohort (n = 2,132) was used 
to create the PIRO score, identify independent 
predictors of mortality, and the prognostic perfor-
mance was then investigated in independent inter-
nal (n = 4,618) and external (n = 1,004) validation 
cohorts. A number of covariates were analyzed with 
multivariate regression, and significantly revealed 
an association with mortality for each PIRO cate-
gory: Predisposition (P) consists of sub-variables 
of premorbid and comorbid factors such as age, 
history of disease or presence of an aggravating 
disease (COPD, liver disease, malignancies) and 
nursing home resident, Infection (I) consists of 
the presence of pneumonia and or other sources 
of infection, Response (R) consists of sub-clinical 
and laboratory variables of host response to infec-
tion i.e. respiration rate, bands and heart rate, and 
Organ Dysfunction (O) consists of sub-variables 
of response to organ dysfunction in cardiovascu-
lar (systolic blood pressure), respiratory (presence 
of respiratory failure or hypoxemia), renal (BUN 
value), hematologic (the platelet count) and meta-
bolic (the lactate level). The PIRO score was strati-
fied into 5 (five) intervals; <5, 5-9, 10-14, 15-19 and 
≥ 20 and the mortality rate 0 – 0.3%, 1.9 – 3.7%, 
6.5 – 10.4%, 20.1 – 32% and 38.9 – 57% respec-
tively. The model validation of PIRO score in this 
study showed an accurately predicted mortality in 
both validation sets with respective areas under the 
receiver operating characteristics curve of 0.86 and 
0.83, with a clear stepwise, increased in mortality 
with an increasing PIRO score, but the overall 
mortality was low.10,18
A prospective observational ED study of 240 
patients presenting evidence of shock, hypox-
emia, or other organ failure was conducted by 
Macdonald et  al (2014). In this study, the PIRO 
score was compared with the Sequential Organ 
Failure Assessment (SOFA) to predict mortality in 
ED patients with features suggesting severe sepsis 
or septic shock in the ED. The study revealed area 
under curve ROC (AUCR) for mortality was 0.86 
(95% confidence interval [CI] = 0.80 – 0.92) for 
PIRO, and 0.78 (95% CI = 0.71 – 0.87) for SOFA 
scores. Furthermore, the mortality increased with 
an increasing PIRO scores: PIRO < 5, 0%; PIRO 5 to 
9, 5%; PIRO 10 to 14, 5%; PIRO 15 to 19, 37%; and 
PIRO ≥ 20, 80% (p < 0.001).10 This data suggested 
that PIRO scores performed better than SOFA 
scores, and PIRO model may have better sensitivity 
for 30-day mortality prediction. 
The advance of disease-specific (pneumonia) 
severity scoring and risk modification tools in clin-
ical trials of VAP would signify an advancement in 
this clinical trial. A number of independent predic-
tors of outcome of pneumonia must be considered 
in this pneumonia risk stratification, including 
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severity of disease and illness, the presence of organ 
dysfunction, underlying diseases and comorbid-
ities, and specific causative pathogens. Therefore, 
the PIRO score for VAP is a suitable concept for the 
consideration.
BIOMARKERS – THEIR ROLE IN 
PREDICTION OF DISEASE SEVERITY 
AND MORTALITY IN PATIENT WITH 
VENTILATOR ACQUIRED PNEUMONIA 
IN INTENSIVE CARE UNIT
Biologic markers are defined as molecular markers, 
cellular, or biochemical which are measured objec-
tively in human tissues or fluids and play a vigorous 
role in supporting physiological processes, indi-
cating pathogenic processes or pharmacological 
responses to a therapeutic intervention, establishing 
the diagnosis and assessing severity and prognosis. 
Important biomarkers that commonly used for 
monitoring in ICU-related infections are leuko-
cyte count, CRP, and Procalcitonin.19-21 C-Reactive 
Protein (CRP) is an acute-phase protein produced 
by the liver, whereas Procalcitonin (PCT) is the 
pre-hormone of calcitonin secreted by Parafollicular 
C-cells of the thyroid gland and markedly elevated 
in systemic infection and sepsis. 
The role of PCT and CRP biomarkers in predict-
ing the survival and mortality in patients with VAP 
has been assessed in several studies.19-21 An obser-
vational cohort study was conducted in 71 patients 
with VAP by Seligman et  al (2011). The accuracy 
of CRP, PCT, and SOFA was compared in predict-
ing the VAP mortality. The result demonstrated 
an association of high PCT value with mortality 
as well as SOFA score. Another study by Afifi et al 
(2015) in 50 patients with VAP has also found that 
the PCT kinetics can be used to assess prognosis in 
VAP because it can discriminate between survivor 
and non-survivor significantly during the course 
of the VAP with p < 0.001. The CRP is useful as a 
diagnostic but not as a prognosis biomarker in VAP. 
However, the studies also failed to stratify the 
severity of disease, did not count the presence of 
underlying diseases and comorbidities, were very 
limited in specificity and sensitivity, remain expen-
sive in some countries and are not systematically 
used at hospitals, placing them in practical and are 
out of reach from poor patients. Those two biomark-
ers also do not always perform satisfactorily high-
lighting the need to identify better biomarkers for a 
significant improvement of the predictive value.21,22
The Neutrophil-to-lymphocyte ratio (NLR) is 
a simple biomarker and often used in predicting 
mortality in ICU patients. It is an easily avail-
able biomarker that can be calculated based on a 
complete blood count. This ratio proves its useful-
ness in mortality stratification in the incidence of 
heart disease, myocardial infarction as a prognostic 
factor in some cancers, or as a predictor and marker 
of inflammation or pathological infection, postop-
erative and in the evaluation of systemic inflamma-
tory responses.22-24 
Several studies have assessed the potential of 
NLR to help to predict the prognosis of patients with 
CAP and/or VAP.22,25 A study cohort consisted of 
395 patients diagnosed with  community-acquired 
pneumonia (CAP) was conducted by Jager et  al 
(2010). The study showed an area under the curve 
(AUC) of 0.701 in predicting mortality in CAP, and 
it was better than the AUC for the neutrophil count, 
WBC count, lymphocyte count and CRP level 
(0.681, 0.672, 0.630 and 0.565, respectively).26 A 
retrospective study by Yang et al (2012) in a consec-
utive series of 318 adult patients which examined 
the prediction of NLR towards in-hospital mortal-
ity of adults with CAP showed an index predicted 
in-hospital mortality with a sensitivity of 82.61% 
and specificity of 72.20% (area under ROC curve, 
0.799).22 
A prospective trial was conducted by Liu et  al 
(2016) on consecutive 333 adult patients with 
sepsis due to some conditions including CAP, HAP 
and VAP admitted to the ICU. In this prospective 
observational study, they evaluated the potential 
association of NLR on ICU admission with the 
clinical prognosis and disease severity. They found 
that NLR had a modest power for predicting 28-day 
mortality as suggested by the area under the curve 
(AUC) of 0.695 ± 0.036. Multivariate linear regres-
sion also pointed out that increased NLR levels 
were associated with unfavorable outcome inde-
pendently of the effect of possible confounders.27
It is clear that the NLR is a simple and promis-
ing marker for assessing the severity of CAP and/
or VAP and identifying adult patients at elevated 
risk of in-hospital mortality. However, in general 
biomarkers alone are clearly less suited in the 
prediction of prognosis and severity of disease, and 
the use of a biomarker alone for severity assessment 
remains premature.17
INTEGRATION OF CLINICAL 
SCORES PIRO AND BIOMARKERS 
NLR IN PREDICTING MORTALITY 
OF VENTILATOR-ASSOCIATED 
PNEUMONIA
The significance of clinical scoring and biological 
markers in predicting mortality of VAP when used 
alone has been examined in this review. But when 
they were used in conjunction or integrated, its 
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predictive accuracy would enhance and provide 
good validity in predicting the mortality risk in a 
wide range of patient especially VAP patients in 
ICUs. 
The PIRO scoring system was comprehensive 
and performed better than the other available scor-
ing system for predicting VAP mortality. However, 
the assessment variables are not entirely available 
for all health facilities. The modification or integra-
tion of PIRO with a simple and useful biomarker is 
a key to this problem. One possibility is the neutro-
phil-lymphocyte count ratio (NLR), an easily 
determined index already widely used to evaluate 
systemic inflammatory responses.22 
There are some studies conducted on this inte-
gration, especially in patients with CAP, but very 
limited data are available concerning the integration 
of PIRO score with biomarker NLR in VAP. Current 
data available is only a prospective, multi-center, 
observational study designed by Granja et al (2013) 
to evaluate the epidemiology of community and 
healthcare-associated sepsis in patients who were 
admitted in ICUs.28 In this study, they identified 
specific variables related with each of the four 
components of PIRO, including biomarkers CRP 
integration and a dynamic view of the patient daily 
clinical course. This study was the first to introduce 
and integrate the CRP biomarkers to the PIRO 
staging system and showed a very good discrimi-
natory ability (AUC 0.85, CI95%: 0.82–0.88) with 
p < 0.001.28
This study showed that the integration of the 
clinical score PIRO with biomarker CRP has 
increased the ability of the tools and enhanced 
its predictive accuracy concerning mortality in 
predicting the mortality risk of the patients with 
sepsis in ICU. Further validation of these biomark-
ers and more advanced biomarker discoveries or 
other integration with clinical scores are required 
in prospective trials to explain their application in 
clinical practice. 
CONCLUSION
The conclusion of this review based on the avail-
able data suggests that the PIRO scoring system 
performed better, was well-discriminated and 
had better sensitivity for 30-day mortality predic-
tion in VAP patients than other available clin-
ical scores. In the setting of limited financial and 
laboratory resources, the modification of PIRO 
score in conjunction with a simple and useful 
NLR biomarker seems to be a reasonable approach 
for the evaluation of these patients. Based on the 
inflammatory response of each patient that has 
been assessed with PIRO score, the biomarker may 
improve the mortality prediction of the prognosis. 
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